Reimbursed with a limitationOriginator productATC V10XX03

Xofigo

Xofigo is an originator product from Bayer (Schweiz) AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 4'168.55 to CHF 4'168.55 depending on the pack; the patient co-payment is 10 per cent plus the deductible.

Core data

Authorisation holder: Bayer (Schweiz) AG
ATC code: V10XX03
IT group: 17.02 Radio-Therapeutika
Active substances: Radium-223 dichloridum
Preparation type: Originator product
On the SL since: 01/10/2014
Last price change: 01/06/2026
Co-payment: 10%

Prices per pack

The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.

Xofigo Price table As of 17/09/2026
Dosage form	Pack size	Ex-factory price	Public price	Valid from	Cat.	GTIN
Inj Lös 1100 kBq Ra-223/ml	Vial 6 ml	CHF 3'817.85	CHF 4'168.55	01/06/2026	A	7680627320014

Limitation

This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.

The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.

FOPH wordingIndication 20252.01Valid from 01/06/2026

XOFIGO wird bei Patienten mit kastrationsresistentem Prostatakarzinom (CRPC) und symptomatischen Knochenmetastasen ohne bekannte viszerale Metastasen vergütet, wenn eine Chemotherapie nicht indiziert ist oder bei Progredienz nach Docetaxel und dabei nicht gleichzeitig mit einer Androgendeprivationstherapie (ADT) der zweiten Generation (zum Beispiel Abirateronacetat und Enzalutamid), nicht mit zielgerichteten Therapien (zum Beispiel Olaparib) sowie nicht mit Cabazitaxel oder Docetaxel. Es werden maximal 6 Therapiezyklen vergütet. Bei nicht orchiektomierten Patienten soll eine antiandrogene Behandlung zur Suppression des Testosteronspiegels auf Kastrationsniveau weitergeführt werden.

FAQ

Is Xofigo covered by Swiss health insurance?

Yes, but only under conditions. Xofigo is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.

What does Xofigo cost in Switzerland?

The public price is the maximum price set by the FOPH and for Xofigo ranges from CHF 4'168.55 to CHF 4'168.55 per pack. The ex-factory price ranges from CHF 3'817.85 to CHF 3'817.85. Pharmacies may not charge more, but may charge less.

Correct or complete this entry

Market access

Do you need your product on the Specialities List?

Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.

Independent directory
Official FOPH data
Website in eight languages

Request a market access call View information